MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

Search

Penumbra Inc

Geschlossen

BrancheGesundheitswesen

237.34 -2.54

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

235.79

Max

243.57

Schlüsselkennzahlen

By Trading Economics

Einkommen

5.5M

39M

Verkäufe

8.6M

324M

KGV

Branchendurchschnitt

232.122

39.564

Gewinnspanne

12.101

Angestellte

4,500

EBITDA

131K

49M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+29.85% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

29. Juli 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-1.1B

9.6B

Vorheriger Eröffnungskurs

239.88

Vorheriger Schlusskurs

237.34

Nachrichtenstimmung

By Acuity

50%

50%

174 / 376 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Bearish Evidence

Penumbra Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

11. Juli 2025, 22:19 UTC

Akquisitionen, Fusionen, Übernahmen

FCC Approves U.S. Cellular Sale to T-Mobile

11. Juli 2025, 17:28 UTC

Wichtige Markttreiber

SharpLink Gaming Gains on Ethereum Purchase

11. Juli 2025, 16:57 UTC

Ergebnisse

BASF Cuts Outlook on Global Economy Uncertainty

11. Juli 2025, 21:45 UTC

Market Talk

Fitch Affirms Germany's Rating, Sees Deficit, Debt Rising -- Market Talk

11. Juli 2025, 19:46 UTC

Akquisitionen, Fusionen, Übernahmen

Kraft Heinz Might Split Up, Report Says. What Investors Need to Know. -- Barrons.com

11. Juli 2025, 19:45 UTC

Market Talk

Crude Futures Post Back-to-Back Weekly Gains -- Market Talk

11. Juli 2025, 19:05 UTC

Market Talk

U.S. Natural Gas Futures Post Third Straight Weekly Loss -- Market Talk

11. Juli 2025, 18:18 UTC

Market Talk

Canada Officials Tight-Lipped on Next Steps in Trump Trade Talks -- Market Talk

11. Juli 2025, 17:35 UTC

Market Talk

Canada Should Target Lower Sectoral Tariffs, Import Quotas in US Trade Talks -- Market Talk

11. Juli 2025, 17:26 UTC

Market Talk

U.S. Oil Rig Count Down by 1 to 424 -- Market Talk

11. Juli 2025, 16:53 UTC

Market Talk

Crude Futures Add to Early Gains -- Market Talk

11. Juli 2025, 16:42 UTC

Ergebnisse

BASF Cuts Outlook on Global Economic Uncertainty

11. Juli 2025, 16:08 UTC

Market Talk

Rise in Canadian Staycations May Help Explain Labor Market Strength -- Market Talk

11. Juli 2025, 16:05 UTC

Ergebnisse

BASF Will Publish Half-Year Results on July 30

11. Juli 2025, 16:04 UTC

Market Talk

Global Equities Roundup: Market Talk

11. Juli 2025, 16:04 UTC

Market Talk

Senior Housing Shortage Gives REITs Pricing Power -- Market Talk

11. Juli 2025, 16:03 UTC

Ergebnisse

BASF: Guidance Cut Is Due to Ongoing Macroeconomic, Geopolitical Uncertainties

11. Juli 2025, 16:02 UTC

Ergebnisse

BASF Continues to Expect Free Cash Flow Between EUR400M and EUR800M in 2025

11. Juli 2025, 16:01 UTC

Ergebnisse

BASF Had Seen Ebitda Before Special Items Between EUR8B and EUR8.4B in 2025

11. Juli 2025, 16:00 UTC

Ergebnisse

BASF Now Sees Ebitda Before Special Items Between EUR7.3B and EUR7.7B in 2025

11. Juli 2025, 15:59 UTC

Ergebnisse

BASF Cuts 2025 Earnings View

11. Juli 2025, 15:58 UTC

Ergebnisse

Nvidia's CEO Has Sold a Million Shares. He Has Millions More to Sell. -- Barrons.com

11. Juli 2025, 15:57 UTC

Ergebnisse

BASF 2Q EBIT Before Special Items EUR810M

11. Juli 2025, 15:54 UTC

Ergebnisse

BASF: Analysts Had Expected 2Q Sales of EUR15.80B

11. Juli 2025, 15:54 UTC

Ergebnisse

BASF 2Q Sales Fell 2.1% on Year

11. Juli 2025, 15:53 UTC

Ergebnisse

BASF 2Q Sales EUR15.77B

11. Juli 2025, 15:52 UTC

Ergebnisse

BASF: This Was in Line With Consensus Estimates

11. Juli 2025, 15:52 UTC

Ergebnisse

BASF 2Q Ebitda Before Special Items EUR1.77B

11. Juli 2025, 15:49 UTC

Ergebnisse

BASF Reports Preliminary 2Q Figures, Adjusts 2025 Outlook

11. Juli 2025, 15:41 UTC

Market Talk

Oil, Gas Prices Not Seen Supporting Drilling Boom -- Market Talk

Peer-Vergleich

Kursveränderung

Penumbra Inc Prognose

Kursziel

By TipRanks

29.85% Vorteil

12-Monats-Prognose

Durchschnitt 316.67 USD  29.85%

Hoch 340 USD

Tief 260 USD

Basierend auf 16 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Penumbra Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

16 ratings

12

Buy

4

Halten

0

Sell

Technischer Score

By Trading Central

288.28 / 292.9394Unterstützung & Widerstand

Kurzfristig

Bearish Evidence

Mittelfristig

Bullish Evidence

Langfristig

Weak Bullish Evidence

Stimmung

By Acuity

174 / 376 Ranking in Gesundheitswesen

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Überdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Penumbra Inc

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX Select, BENCHMARK, BMX96, BMX81, DDC, SENDit, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization Device, aspiration tubing, and aspiration pump under the Penumbra RED, JET, ACE, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that includes the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as Penumbra SMART COIL, a detachable coil to treat patients with a wide range of neurovascular lesions; and POD400 and PAC400 brands. In addition, the company provides peripheral embolization products, such as Ruby Coil System consisting of detachable coils for peripheral applications; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers an immersive 3D computer-based technology platform under the real immersive system brand; and neurosurgical tools, such as Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.